Skip to main content

Table 3 Mean cognitive function in the municipality and drug groups by follow-up time point. Intention to treat analyses

From: The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design

Groups

Moments of follow-up

 

Baseline, n = 180

4 months, n = 158

8 months n = 153

12 months,* n = 146

p-value1

p-value2

MMSE ± SD**

Municipality

Stimulation (n = 103)

22.9 ± 4.6

22.1 ± 5.0

22.9 ± 4.5

22.6 ± 5.2

0.15

0.017

Standard care (n = 77)

23.5 ± 4.3

23.8 ± 4.

24.4 ± 4.0

23.9 ± 4.3

  

Drug

Donepezil (n = 90)

23.2 ± 4.2

23.3 ± 4.5

23.8 ± 4.3

23.0 ± 4.9

0.31

0.21

Placebo n = 90

23.1 ± 4.1

22.9 ± 4.8

23.4 ± 4.3

23.3 ± 4.8

  

Clock Drawing Test ± SD**

Municipality

Stimulation

2.9 ± 1.2

2.9 ± 1.1

2.8 ± 1.1

3.0 ± 1.1

0.21

0.071

Standard care

2.8 ± 1.2

3.0 ± 1.2

3.1 ± 1.1

3.1 ± 1.1

  

Drug

      

Donepezil

2.9 ± 1.2

2.8 ± 1.2

2.8 ± 1.2

3.0 ± 1.0

0.56

0.26

Placebo

2.8 ± 1.1

3.0 ± 1.1

3.0 ± 1.0

3.1 ± 1.1

  

ADAS-cog ± SD**

Municipality

Stimulation

18.9 ± 8.7

18.5 ± 8.4

17.0 ± 9.1

16.8 ± 8.5

0.23

0.11

Standard care

17.4 ± 7.0

16.1 ± 6.9

15.7 ± 8.2

15.9 ± 8.0

  

Drug

Donepezil

18.6 ± 7.6

17.7 ± 7.8

16.3 ± 8.8

16.3 ± 8.4

0.59

0.24

Placebo

17.9 ± 8.4

17.1 ± 7.9

16.5 ± 8.6

16.4 ± 8.2

  
  1. *n varies due to dropouts during follow-up. ** Standard deviation. p-value1 = Equal time trends between groups. p-value2 = Equal time trend between groups adjusted for baseline cognitive function.